lastly according to the dr m.d. anderson cancer c
Post# of 148110
$CYDY conversation
@Jing
I can’t wait to read the MDA paper on checkpoint inhibitors ( dostarlimab) and Leronlimab synergy . This will be breakthrough designation . So it is possible that a BTD will be submitted using the combination of both these molecules after trials